On 20 August 2026, the Ministry of Health (MOH) advised the public — particularly senior citizens — to be wary of unproven claims attached to "hydrogen inhalers" and hydrogen-generating machines circulating on social media. The devices were marketed as treatments for heart disease, diabetes, and high blood pressure, pitched through videos and high-pressure, emotionally targeted sales tactics aimed at older Malaysians.
MOH's statement was blunt: these devices had not been approved by the Medical Device Authority, and under the Medical Device Act 2012 (Act 737), every medical device sold or used in Malaysia must be registered. Selling, distributing, or advertising an unregistered device is a criminal offence. The ministry urged the public to check a device's registration status before buying, and to consult registered medical practitioners rather than sales videos on health decisions.
The device itself is almost beside the point. Pseudoscientific "wellness" products have circulated in Malaysia for years — quantum pendants, magnetic bracelets, ionic foot baths. What deserves scrutiny is the pattern: informal, unverified products consistently outpace verified, university-grade research to reach the same households, targeting the same vulnerabilities.
What it actually costs the rakyat
This isn't an abstract regulatory failure. It has direct financial and health costs, and it falls hardest on the people least equipped to absorb them.
RM552.5m
lost by senior citizens to online scams in Malaysia between 2021–2023, across 5,533 elderly victims — a group that made up only 6.4% of victims but carried a disproportionate share of losses
27.7%
of total scam losses in the first months of one recent year came from senior citizens alone, despite senior citizens being a small fraction of total victims — the same demographic MOH flagged as the hydrogen inhaler's target market
50%
of government research funding is meant to target high-commercialisation-potential R&D under national policy — yet commercialisation outcomes from local universities remain widely described in the research literature as low and unsatisfactory
Act 737
is the same law both a fraudulent seller and a genuine university spin-out must satisfy. One route ignores it entirely; the other can spend years inside it
Where local universities and research institutes are actually stuck
It's tempting to treat this purely as a consumer literacy problem — teach the rakyat to check registration status and the danger goes away. That's necessary but insufficient. The deeper issue is that Malaysia's local universities and research institutes are structurally slow to bring their own validated work to the exact market segment the informal sellers are exploiting. Several problems recur across the research on Malaysian university IPR and commercialisation:
Incentive misalignment
Academic career advancement in Malaysia still rewards publication output — journal rankings, citation counts, grant renewals — far more visibly than it rewards successful commercialisation. A researcher who spends two years navigating licensing and regulatory approval for a health product often gains less institutional credit than one who publishes the underlying study and moves to the next grant cycle. Commercialisation becomes optional effort layered on top of the "real" job, not the job itself.
Under-resourced technology transfer offices
Many university tech transfer offices are small, generalist teams expected to handle IP filing, licensing negotiation, market validation, and regulatory liaison across every discipline at once — from agritech to medical devices. Health-related innovations, which face the heaviest regulatory burden of all, often get the same generic process as a low-risk consumer product, which slows exactly the category most vulnerable to being undercut by unregulated competitors.
Distance from the market it's meant to serve
Research questions are frequently set by funding calls and academic novelty rather than by validated public need. That's not wrong in itself, but it means a genuinely useful, market-ready innovation can sit unlicensed for lack of an obvious commercial partner, while the exact anxiety it could address — an ageing population worried about chronic disease — is being served instead by a seller with no scientific basis and a much shorter path to market.
Low public visibility of what already exists
Even where local universities have produced validated, registered health innovations, the public rarely hears about them with anything like the reach of a viral sales video. There is no consistent, trusted channel where a Malaysian household can discover "this university product does what it claims, and it's registered" — so the informal market fills that attention gap by default, not because it's more convincing, but because it's louder and faster.
The pattern, mapped
The two dangerous cells aren't opposites; they're connected. When validated work sits too long in the bottom-right quadrant, public attention and even genuine need drift toward the top-left by default — because the unverified alternative is simply there, now, promising relief. Closing that gap isn't only about stopping bad actors; it's about local research institutions moving with enough urgency that the rakyat has a real, visible, verified option before the informal seller reaches them first.
Why the fake product wins the race to market
It's not that sellers of unverified products are more capable. It's that they are structurally unburdened by everything a genuine R&D-based product has to carry. In the Malaysian context specifically, a few mechanics explain the speed gap:
Five structural advantages the informal seller has
- Zero regulatory cost of entry. A university spin-out must clear ethics approval, IP protection, clinical or technical validation, and MDA/NPRA registration before a single unit is sold. An unregistered seller simply posts a video. There is no gate to fund, staff, or wait for — the entire cost structure of compliance is absent from their business model.
- Social media rewards emotional claims over accurate ones. Platforms amplify whatever earns engagement — a confident cure claim outperforms a hedged, evidence-qualified one every time. A genuine researcher trained to say "may support" or "shows promise in early trials" is competing against a seller free to say "cures."
- Distribution matches the target audience precisely. Sellers of these products deliberately reach older Malaysians through the platforms and formats — WhatsApp forwards, Facebook and TikTok videos, family group chats — that this demographic already trusts, while university communications typically live in press releases, journals, or institutional websites that this same audience rarely sees.
- No institutional liability to protect. A university risks its name, its funders' confidence, and future ethics approvals if a product underperforms — so it moves cautiously. An anonymous or fly-by-night seller has no comparable reputation at stake and often no fixed identity to hold accountable once complaints start.
- Enforcement is reactive, not preventive. MOH and the MDA can only warn the public and pursue action after a product is already circulating and has already been reported. There is no equivalent pre-market checkpoint for social media advertising, as there is for registered products in pharmacies or clinics — so by the time a warning is issued, the sales window has often already done its damage.
Why universities and research institutes are slow to fight back
Beyond the commercialisation friction already discussed, there's a separate, related question: why don't local universities more actively counter these products in public once they appear? A few recurring reasons show up across how Malaysian institutions are structured to operate:
Public engagement isn't anyone's job
Responding to a viral health scam publicly and quickly falls between departments — it's not core research output, not quite official MOH business, and rarely has a named owner inside a university. Without a clear mandate, the natural response is silence rather than initiative.
Institutional caution around public statements
Universities are risk-averse about anything that could be read as a formal public claim, medical advice, or implicit endorsement — even a statement debunking a fraudulent product typically has to pass through communications, legal, and sometimes ethics review before release. By the time internal sign-off is complete, the news cycle and the sales window have often both moved on.
Academic timelines don't match viral timelines
A university's natural response to a dubious health claim is to study it properly — which is exactly right scientifically, and exactly too slow reputationally. A rigorous rebuttal that takes months arrives long after the product has already extracted its cost from the people who bought it.
Fragmented responsibility with enforcement bodies
Detecting and warning about unregistered products falls to MOH and the MDA; developing and commercialising genuine alternatives falls to universities. Because no single body owns both halves, universities have little structural reason to treat an MOH warning as their own cue to visibly step forward with what they've already validated.
How to improve it
A four-part response for universities and research institutes
- Reward commercialisation as career output, not extra credit. Promotion and grant-renewal criteria should count successful licensing, registration, and market adoption alongside publication metrics — otherwise, researchers are rational in treating commercialisation as optional.
- Give health-related innovations a dedicated, faster internal track. Not every category of invention carries the same regulatory weight. Tech transfer offices should route medical and health products through specialists who understand Ministry of Health and device-registration requirements from the earliest stage of development, not after the prototype is finished.
- Teach regulatory and market literacy inside postgraduate training. Researchers are rigorously trained in methods and evidence, rarely in how quickly an unregulated competitor can exploit the exact claim their own work is trying to prove responsibly. That gap should close inside the research degree, not after graduation.
- Build a public-facing trust channel for verified local innovation. When MOH issues a warning about a fraudulent product, that is also the moment the public is most receptive to hearing what a legitimate, registered alternative from a local university looks like — universities should have a standing, recognisable way to be part of that conversation, not a one-off press release.
What this means for decision-makers
For research leaders: the competition for a household's trust isn't the university across town — it's whoever reaches that household first with a confident claim, evidence or not. Treat speed-to-verified-market as part of the research mission, not an afterthought. For institutional leadership: an academic incentive structure that doesn't reward commercialisation is quietly ceding public health ground to anyone willing to move faster and check less. For the rakyat: registration status is checkable, in minutes, before any purchase — and that single habit remains the most immediate protection available today, regardless of how quickly institutions reform.